Rhabdomyolysis precipitated by a sitagliptin-atorvastatin drug interaction

被引：20

作者：

Bhome, R. ^{[1
]}

Penn, H. ^{[1
]}

机构：

[1] Northwick Pk Hosp & Clin Res Ctr, Dept Rheumatol, Harrow HA1 3UJ, Middx, England

来源：

DIABETIC MEDICINE | 2012年 / 29卷 / 05期

关键词：

D O I：

10.1111/j.1464-5491.2011.03502.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Diabet. Med. 29, 693694 (2012)

引用

页码：693 / 694

页数：2

共 5 条

[1] Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial [J].

Arechavaleta, R. ;

Seck, T. ;

Chen, Y. ;

Krobot, K. J. ;

O'Neill, E. A. ;

Duran, L. ;

Kaufman, K. D. ;

Williams-Herman, D. ;

Goldstein, B. J. .

DIABETES OBESITY & METABOLISM, 2011, 13 (02) :160-168

[2] Safety of statins - Focus on clinical pharmacokinetics and drug interactions [J].

Bellosta, S ;

Paoletti, R ;

Corsini, A .

CIRCULATION, 2004, 109 (23) :50-57

[3] Rhabdomyolysis Caused by a Potential Sitagliptin-Lovastatin Interaction [J].

DiGregorio, Robert V. ;

Pasikhova, Yanina .

PHARMACOTHERAPY, 2009, 29 (03) :352-356

[4] Renal failure and rhabdomyolysis associated with sitagliptin and simvastatin use [J].

Kao, D. P. ;

Kohrt, H. E. ;

Kugler, J. .

DIABETIC MEDICINE, 2008, 25 (10) :1229-1230

[5] Metabolism and excretion of the dipeptidyl peptidase 4 inhibitor [14C]sitagliptin in humans [J].

Vincent, Stella H. ;

Reed, James R. ;

Bergman, Arthur J. ;

Elmore, Charles S. ;

Zhu, Bing ;

Xu, Shiyao ;

Ebel, David ;

Larson, Patrick ;

Zeng, Wei ;

Chen, Li ;

Dilzer, Stacy ;

Lasseter, Kenneth ;

Gottesdiener, Keith ;

Wagner, John A. ;

Herman, Gary A. .

DRUG METABOLISM AND DISPOSITION, 2007, 35 (04) :533-538

← 1 →